Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
02 2019
Historique:
received: 09 08 2018
accepted: 13 10 2018
pubmed: 28 11 2018
medline: 16 3 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

Tafamidis meglumine, a transthyretin (TTR) stabilizer, is effective in delaying the progression of neuropathy in TTR amyloidosis with Val30Met mutations. However, its efficacy in TTR amyloid cardiomyopathy is not fully elucidated. Herein, we report a 73-year-old Japanese man with a diagnosis of TTR amyloid cardiomyopathy with Val30Met mutation treated with tafamidis. To evaluate treatment response, cardiac magnetic resonance imaging was performed before and after 12 months of tafamidis treatment. Native T1, extracellular volume, and left ventricular mass showed no obvious worsening, and findings of other diagnostic studies also supported the efficacy of tafamidis to delay the progression of amyloid cardiomyopathy. Our case suggests that serial native T1 and extracellular volume may be novel non-invasive imaging methods to monitor the treatment response to TTR stabilizers in cardiac amyloidosis and also that tafamidis may be effective in suppressing cardiac progression in TTR amyloid cardiomyopathy with Val30Met mutation.

Identifiants

pubmed: 30478886
doi: 10.1002/ehf2.12382
pmc: PMC6352892
doi:

Substances chimiques

Benzoxazoles 0
tafamidis 8FG9H9D31J

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

232-236

Informations de copyright

© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

Am J Cardiol. 2011 Jul 15;108(2):285-9
pubmed: 21550574
J Clin Pharm Ther. 2014 Jun;39(3):225-33
pubmed: 24749898
J Am Coll Cardiol. 2017 Jul 25;70(4):466-477
pubmed: 28728692
Cardiology. 2017;137(2):74-77
pubmed: 28152524
J Cardiovasc Transl Res. 2015 Mar;8(2):117-27
pubmed: 25743445
Clin Res Cardiol. 2017 Apr;106(4):311-316
pubmed: 28116497
Circ Heart Fail. 2015 May;8(3):519-26
pubmed: 25872787
Circ Heart Fail. 2018 Apr;11(4):e004769
pubmed: 29615436
J Cardiovasc Transl Res. 2013 Dec;6(6):1011-20
pubmed: 24101373
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
J Cardiol. 2018 Feb;71(2):135-143
pubmed: 29113705
ESC Heart Fail. 2019 Feb;6(1):232-236
pubmed: 30478886
Am J Cardiol. 2017 Dec 1;120(11):2041-2048
pubmed: 28947306
J Neurol Sci. 2009 Dec 15;287(1-2):178-84
pubmed: 19709674
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
J Neurol Sci. 2016 Mar 15;362:266-71
pubmed: 26944161

Auteurs

Yasuhiro Shintani (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Atsushi Okada (A)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Yoshiaki Morita (Y)

Department of Radiology, National Cerebral and Cardiovascular Center, Osaka, Japan.

Yasuhiro Hamatani (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Masashi Amano (M)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Hiroyuki Takahama (H)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Makoto Amaki (M)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Takuya Hasegawa (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Keiko Ohta-Ogo (K)

Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan.

Hideaki Kanzaki (H)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Hatsue Ishibashi-Ueda (H)

Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan.

Satoshi Yasuda (S)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Chihiro Shimazaki (C)

Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.

Tsuneaki Yoshinaga (T)

Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.

Masahide Yazaki (M)

Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Department of Biological Sciences for Intractable Neurological Diseases, Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan.

Yoshiki Sekijima (Y)

Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Department of Biological Sciences for Intractable Neurological Diseases, Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan.

Chisato Izumi (C)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH